论文部分内容阅读
目的:观察吲哚美辛栓联合盐酸坦洛新治疗ⅢB型前列腺炎的疗效。方法:选择ⅢB型前列腺炎220例,随机分为对照组和观察组各110例。对照组给予口服盐酸坦洛新治疗,观察组在对照组治疗基础上加用吲哚美辛栓肛塞治疗。比较两组疗效、美国国立卫生研究院慢性前列腺炎症状评分(NIH-CPSI)及不良反应发生情况。结果:观察组总有效率88.2%,非常显著高于对照组的73.6%(P<0.01)。治疗后,两组疼痛、尿路症状、生活质量评分及总分分值均非常显著低于治疗前(P<0.01),同时,观察组上述各项分值又显著或非常显著低于对照组治疗后(P<0.05,P<0.01)。两组不良反应发生率差异不显著(P>0.05)。结论:吲哚美辛栓联合盐酸坦洛新治疗ⅢB型前列腺炎疗效优于单用盐酸坦洛新治疗。
Objective: To observe the curative effect of indometacin combined with tamsulosin hydrochloride on type ⅢB prostatitis. Methods: 220 cases of type ⅢB prostatitis were randomly divided into control group and observation group of 110 cases. The control group was given oral tamsulosin hydrochloride. The observation group was treated with indometacin suppository on the basis of the control group. The curative effects of the two groups were compared, and NIH-CPSI and adverse reactions were observed. Results: The total effective rate in observation group was 88.2%, which was significantly higher than that in control group (73.6%, P <0.01). After treatment, the scores of pain, urinary tract symptoms, quality of life and total score of the two groups were significantly lower than those before treatment (P <0.01), meanwhile, the above scores of the observation group were significantly or very significantly lower than those of the control group After treatment (P <0.05, P <0.01). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion: Indometacin suppository combined with tamsulosin hydrochloride is superior to tamsulosin hydrochloride alone in the treatment of type ⅢB prostatitis.